Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Thursday, 4 November 2021, 10:06 HKT/SGT
Share:
    

Source: Eisai
Eisai and Digital Garage, Inc. Jointly Launch "Onlab Bio Dementia (Open Network Lab BioHealth Dementia Innovation Challenge)"
A Collaborative Cultivation Program with Dementia-related Startups

TOKYO, Nov 4, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that it launches the "Open Network Lab BioHealth Dementia Innovation Challenge (Onlab Bio Dementia)", a collaborative cultivation program jointly implemented with Digital Garage, Inc., with the aim of contributing to solving issues related to dementia and starts recruiting startups for teams to participate in the program. The program is designed to resolve various issues related to dementia with technology and science by promoting open innovation between startups and Eisai and DG, and to realize the Dementia Inclusive Society.

The program "Onlab Bio Dementia" calls for Japanese and global startups that wish to collaborate with Eisai and DG by utilizing their unique and outstanding technologies or services to solve issues related to dementia, such as brain health check and maintenance, disease awareness and testing, accurate diagnosis and confirming effectiveness of treatment (drug / non-drug), and providing care that contribute to the improvement of QOL (quality of life).

The program will help selected startups for the business growth related to dementia by combining Eisai and DG's assets, including Eisai's wealth of experience and knowledge in medicine creation activities and disease awareness activities in the field of dementia, DG's business development track record and experience in the digital domain such as AI, blockchain, and digital health, and the management know- how and mentoring that DG has acquired through its efforts to provide business support to and invest in startups such as "Onlab". In this program, Eisai and DG will implement the "Open Innovation Program" aiming to create consortium, business alliance, and investment by multiplying the technologies and services of startups with the resources of Eisai and DG, considering collaboration, and conducting demonstration experiments, etc. In addition, the "Accelerator Program" will provide mentoring by experts in various field to accelerate the business growth of startups in the seed and early stages.

Eisai has set its new medium-term business plan "EWAY Future & Beyond", where the perspective will be shifted from that of patients to The People or each consumer. In "EWAY Future & Beyond", with "empowering The People to realize their fullest life" as the vision, Eisai will utilize the latest digital technology such as AI and aim to remove the anxiety of "The People," with delivering not only pharmaceutical products but also solutions to The People. For this, Eisai is progressing to build the Eisai Universal Platform (EUP) which delivers packaged solutions in addition to pharmaceutical products through synergies between the technologies of various external partners and its own R&D. In this program, which is a collaboration between Eisai and DG, Eisai will expand its contribution to "The People" based on EUP, with acquiring the opportunity for investment and collaboration in addition to building a new network with startups.

Media Inquiries:
Public Relations Department
Eisai Co., Ltd.
+81-(0)3-3817-5120


Topic: Press release summary
Source: Eisai

Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2022 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Jan 20, 2022 08:56 HKT/SGT
Eisai: Results From Pivotal Phase 3 Study 309/KEYNOTE-775 Trial of LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) in Advanced Endometrial Carcinoma
Jan 19, 2022 16:36 HKT/SGT
Eisai Listed as a Global 100 Most Sustainable Corporation for the Sixth Time
Jan 19, 2022 09:06 HKT/SGT
Eisai's Anti-amyloid Beta Protofibril Antibody Lecanemab Selected as the Background Therapy for the Tau Nexgen Study
Jan 17, 2022 10:44 HKT/SGT
Eisai to Present Abstracts on Lenvatinib at 2022 ASCO Gastrointestinal Cancers Symposium
Jan 13, 2022 12:26 HKT/SGT
Eisai to Launch Digital Too "Cogmate" in Taiwan and Hong Kong for Self-Assessment of Brain Performance (Brain Health)
Jan 6, 2022 10:09 HKT/SGT
Eisai Enters Into Exclusive Licensing Agreement with Roivant Concerning Investigational Anticancer Agent H3B-8800, a Splicing Modulator
Dec 24, 2021 08:26 HKT/SGT
Investigational Alzheimer's Disease Therapy Lecanemab Granted FDA Fast Track Designation
Dec 21, 2021 09:23 HKT/SGT
Biogen Announces Reduced Price for Aduhelm to Improve Access For Patients With Early Alzheimer's Disease In The United States
Dec 20, 2021 12:35 HKT/SGT
Eisai Enters into Commercialization and Distribution Agreement with Gilead for JAK Inhibitor Filgotinib in Asia
Dec 6, 2021 11:30 HKT/SGT
Eisai to Present Abstracts on Oncology Products And Pipeline at 44th Annual San Antonio Breast Cancer Symposium
More news >>
 News Alerts
Copyright © 2022 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: